MYL9 and prostate adenocarcinoma: High expression of MYL9 in ovarian serous cystadenocarcinoma indicated worse DFS; MYL9 in adrenal cortical carcinoma, prostate adenocarcinoma, and kidney renal clear cell carcinoma showed high DSS expression, and RFS was worse (Figure S1A).